Optimizerx Corp Stock Price, News & Analysis

OptimizeRx (NASDAQ: OPRX) has announced a strategic partnership with Lamar Advertising Company (NASDAQ: LAMR) to transform healthcare out-of-home (OOH) advertising. The collaboration integrates OptimizeRx's patented Micro-Neighborhood® Targeting (MNT) data with Lamar's nationwide advertising inventory, enabling precise targeting of healthcare audiences at the ZIP+4 level.

The partnership allows pharmaceutical and healthcare brands to leverage disease prevalence data for targeted OOH campaigns while maintaining privacy compliance. Key benefits include granular clinical geographic targeting, cost-effective scale compared to linear TV, nationwide reach across Lamar's network, measurable results, and strategic media mix integration.

OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider, has announced significant leadership team advancements to accelerate its Rule of 40 strategy, which focuses on balancing growth with increased profitability.

Key appointments include: Ed Stelmakh as Chief Financial & Strategic Officer, Theresa Greco continuing as Chief Commercial Officer, Marion Odence-Ford as Chief Legal & Administrative Officer, Doug Besch as Chief Product & Technology Officer, Brendan Merrell as Chief Operating Officer, and Andy D'Silva as Chief Business Officer.

Under CEO Steve Silvestro's leadership, these organizational changes aim to enhance execution speed, strategic clarity, and drive the company's goal of achieving Rule of 40 in the next 2-3 years while transitioning to a recurring revenue model.

OptimizeRx (NASDAQ:OPRX) reported strong Q2 2025 financial results, with revenue increasing 55% year-over-year to $29.2 million. The company achieved significant improvements in profitability, posting a GAAP net income of $1.5 million ($0.08 per share) compared to a loss of $4.0 million in Q2 2024.

Gross profit rose 59% to $18.6 million, while Adjusted EBITDA reached $5.8 million, up from $0.5 million year-over-year. The company strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan, $4.0 million above schedule.

Based on strong performance, OptimizeRx raised its full-year 2025 guidance, now expecting revenue between $104-108 million and Adjusted EBITDA between $14.5-17.5 million.

Paynela, an AI-driven healthcare financing company, has appointed William Febbo to its Board of Directors. Febbo, the former CEO of OptimizeRX (NASDAQ: OPRX) from 2016 to 2025, brings over 30 years of healthcare technology experience to the role.

During his tenure at OptimizeRX, Febbo transformed the company into a comprehensive omnichannel platform serving top pharmaceutical companies. He currently serves as Office of the Chairman at Oxbridge Health and on the Board of Directors at LifeMD. The appointment comes as Paynela, recently named a 2024 AWS Generative AI Trailblazer, has achieved a 320x increase in processing speed through its AI-driven healthcare data review platform.

OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has appointed CEO Steve Silvestro to its Board of Directors, effective June 20, 2025. Silvestro, who joined the company in 2019, has served as CEO since March 2025, following his interim CEO role from January 2025.

Under Silvestro's leadership, the company has made significant progress in strengthening its market position. His strategic focus includes enhancing customer experiences, deepening pharmaceutical partnerships, transitioning to a recurring revenue model, and advancing toward Rule of 40 performance. Board Chairperson Lynn Vos expressed confidence in Silvestro's leadership and the company's foundation for long-term value creation.

OptimizeRx (NASDAQ: OPRX) and Simulmedia announced a strategic partnership at Cannes Lions to integrate OptimizeRx's Micro-Neighborhood® Targeting (MNT) technology with Simulmedia's TV and streaming advertising platform. The collaboration enables healthcare brands to target audiences across linear and connected TV using zip-9 geographic disease prevalence mapping while maintaining HIPAA compliance. The partnership allows for rapid deployment of data-driven campaigns, predictive spot-level TV placements, real-time campaign adjustments, and activation across 250+ TV networks. The solution particularly benefits small and mid-size pharmaceutical companies by addressing traditional TV advertising limitations including audience precision, market entry speed, and high minimum spend requirements.

OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has announced its participation in four major investor conferences in May and June 2025. The company will attend:

- B. Riley Securities 25th Annual Investor Conference (May 22) in Marina del Rey, featuring 1x1 meetings and a fireside chat
- Stifel 2025 Boston Cross Sector 1x1 Conference (June 3) at InterContinental Boston
- 45th Annual William Blair Growth Stock Conference (June 5) at Loews Chicago Hotel
- The Citizens Medical Devices and Healthcare Services Forum (June 17) at Boston Harbor Hotel

The latter three events will consist of one-on-one meetings with institutional investors.

OptimizeRx (NASDAQ: OPRX) reported strong Q1 2025 financial results with revenue increasing 11% year-over-year to $21.9 million. The company's gross profit grew 9% to $13.3 million, while GAAP net loss improved to $(2.2) million from $(6.9) million in Q1 2024. Non-GAAP net income reached $1.5 million or $0.08 per diluted share.

Notably, OptimizeRx has increased its full-year 2025 guidance, projecting revenue between $101-106 million and adjusted EBITDA between $13-15 million. The company's performance metrics show strong momentum, with year-to-date contracted revenue up over 20% compared to last year. Additionally, OptimizeRx has successfully converted over 5% of expected 2025 sales into subscription-based revenue streams.

OptimizeRx (NASDAQ: OPRX) has released its 2025 ESG report, highlighting significant progress in environmental, social, and governance initiatives. The company notably improved its ISS ESG rating from the seventh to first decile, achieving prime status. The report emphasizes three key focus areas: Data Protection, Ethics and Governance, and Human Capital. Notable achievements include the introduction of the SPARK employee recognition program and a new Competency Model for career development. The company reported enhanced disclosures on Scope 1 emissions and additional greenhouse gases. OptimizeRx's Dynamic Audience Activation Platform (DAAP), an AI-enabled solution, has shown strong adoption, while the 2024 integration of Healthy Offers (Medicx Health) has strengthened their data and analytics capabilities in healthcare technology solutions.